\-\ Texto\\:\\ \ \(0\)\
\-\ neurological\\ examination\\ \\(march\\ 2011\\)\\ reveals\\ signs\\ of\\ spasticity\\ \\(muscle\\ weakness\\,\\ clonus\\,\\ exaggerated\\ deep\\ tendon\\ reflexes\\)\\.\ \(0\)\
\-\ his\\ drug\\ screen\\ was\\ negative\\ for\\ meth\\ and\\ heroin\\.\\ he\\ did\\ have\\ evidence\\ of\\ rhabdomyolysis\\.\\ \ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/pubmedhealth\\/pmh0001505\\/\ \(0\)\
\-\ he\\ has\\ been\\ receiving\\ chemotherapy\\ schemes\\ and\\ undergoing\\ radiotherapy\\.\\ currently\\,\\ he\\ is\\ in\\ bad\\ clinical\\ condition\\.\\ he\\ suffers\\ from\\ severe\\ muscle\\ weakness\\,\\ cognitive\\ decline\\ and\\ visual\\ impairment\\.\ \(0\)\
\-\ the\\ first\\ brain\\ mri\\ scan\\ \\(march\\ 2008\\)\\ \\ demonstrates\\ the\\ presence\\ of\\ an\\ ill\\-defined\\ \\,\\ t2\\ hyperintense\\,\\ t1\\ hypointense\\ lesion\\ in\\ the\\ medial\\ part\\ of\\ the\\ \\ left\\ temporal\\ lobe\\,\\ with\\ no\\ associated\\ edema\\ or\\ mass\\ effect\\.\\ post\\ contrast\\ images\\ reveal\\ no\\ enhancement\\ of\\ the\\ lesion\\.\\ interestingly\\,\\ there\\ is\\ enlargement\\ of\\ the\\ areas\\ affected\\ by\\ the\\ lesion\\.\ \(0\)\
\-\ brain\\ mri\\ scan\\ \\(march\\ 2011\\)\\ shows\\ an\\ obvious\\ increase\\ in\\ the\\ size\\ of\\ the\\ lesion\\ which\\ extends\\ in\\ the\\ right\\ cerebral\\ hemisphere\\ through\\ the\\ anterior\\ commissure\\ and\\ the\\ corpus\\ callosum\\.\\ the\\ lesion\\ demonstrates\\ mass\\ effect\\ and\\ is\\ characterized\\ by\\ perilesional\\ angiogenic\\ edema\\ and\\ ring\\ pattern\\ of\\ enhancement\\.\\ the\\ lesion\\ contains\\ areas\\ of\\ hemorrhage\\ and\\ necrosis\\.\\ \ \(0\)\
\-\ all\\ the\\ aforementioned\\ features\\ are\\ compatible\\ with\\ the\\ malignant\\ degeneration\\ of\\ a\\ low\\ grade\\ astrocytoma\\ to\\ a\\ high\\ grade\\ brain\\ glioma\\ \\(multiforme\\ glioblastoma\\)\\.\ \(0\)\
\-\ secondary\\ glioblastoma\\,\\ 3\\ yrs\\ from\\ primary\\ astrocytoma\ \(0\)\
\-\ differential\\ diagnostic\\ list\\ of\\ a\\ low\\ \\-grade\\ astrocytoma\\ comprises\\ of\\ infarction\\ \\,\\ lymphoma\\ and\\ encephalitis\\.\ \(0\)\
\-\ the\\ main\\ differential\\ diagnosis\\ of\\ \\ a\\ butterfly\\-type\\ lesion\\ includes\\ \\ \\ gbm\\,\\ lymphoma\\,\\ oligodendroglioma\\ and\\ demyelinating\\ disease\\.\ \(0\)\
\-\ 44\\-year\\-old\\ man\\ presented\\ in\\ 2008\\ with\\ acute\\ onset\\ of\\ confusion\\ and\\ dizziness\\.\\ \\ brain\\ \\ mri\\ scan\\ showed\\ a\\ lesion\\ in\\ the\\ left\\ temporal\\ lobe\\.\\ \\ a\\ biopsy\\ of\\ the\\ lesion\\ was\\ performed\\ in\\ 2009\\.\\ \\ he\\ presented\\ almost\\ exactly\\ three\\ years\\ later\\,\\ in\\ 2011\\,\\ for\\ his\\ regular\\ follow\\-up\\ brain\\ mri\\ scan\\.\\ the\\ clinical\\ profile\\ of\\ the\\ patient\\ now\\ includes\\ progressive\\ cognitive\\ decline\\,\\ severe\\ motor\\ dysfunction\\,\\ muscle\\ weakness\\ and\\ difficulty\\ in\\ speech\\.\ \(0\)\
\-\ the\\ patient\\ underwent\\ a\\ course\\ of\\ radiation\\ treatment\\ on\\ june\\ 2010\\.\\ also\\,\\ he\\ has\\ been\\ receiving\\ chemotherapy\\ on\\ a\\ regular\\ basis\\ \\.\\ so\\,\\ we\\ have\\ to\\ note\\ that\\ part\\ of\\ the\\ tumor\\ necrosis\\ and\\ \\ \\ enhancement\\ as\\ well\\ as\\ some\\ of\\ the\\ white\\ matter\\ t2\\ hyperintesity\\ changes\\ are\\ \\ due\\ to\\ radiation\\ effects\\ \\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ march\\:\\ 0\\.04192163208578863\ \(0\)\
\-\ 2011\\:\\ 0\\.0411214256377545\ \(0\)\
\-\ lesion\\:\\ 0\\.039658220339250864\ \(0\)\
\-\ he\\:\\ 0\\.036215503929615485\ \(0\)\
\-\ brain\\:\\ 0\\.03254875345952863\ \(0\)\
\-\ decline\\:\\ 0\\.028984688458775606\ \(0\)\
\-\ cognitive\\:\\ 0\\.028759616243227083\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.02520265973675921\ \(0\)\
\-\ receiving\\:\\ 0\\.025034518547132192\ \(0\)\
\-\ 2008\\:\\ 0\\.025034518547132192\ \(0\)\
\-\ scan\\:\\ 0\\.024225533776536492\ \(0\)\
\-\ weakness\\:\\ 0\\.02410337736477254\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.023820985112876898\ \(0\)\
\-\ muscle\\:\\ 0\\.023311254937415277\ \(0\)\
\-\ meth\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ \\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/pubmedhealth\\/pmh0001505\\/\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ angiogenic\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ \\-grade\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ butterfly\\-type\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ hyperintesity\\:\\ 0\\.0223177681619405\ \(0\)\
\-\ part\\:\\ 0\\.02097564349116249\ \(0\)\
\-\ regular\\:\\ 0\\.019950992915267578\ \(0\)\
\-\ mri\\:\\ 0\\.01988127448014805\ \(0\)\
\-\ rhabdomyolysis\\:\\ 0\\.019536471228603514\ \(0\)\
\-\ schemes\\:\\ 0\\.019536471228603514\ \(0\)\
\-\ commissure\\:\\ 0\\.019536471228603514\ \(0\)\
\-\ heroin\\:\\ 0\\.01880816218442179\ \(0\)\
\-\ comprises\\:\\ 0\\.01880816218442179\ \(0\)\
\-\ 44\\-year\\-old\\:\\ 0\\.01880816218442179\ \(0\)\
\-\ 2010\\.\\:\\ 0\\.01880816218442179\ \(0\)\
\-\ 2009\\.\\:\\ 0\\.01778166823984416\ \(0\)\
\-\ exactly\\:\\ 0\\.01778166823984416\ \(0\)\
\-\ includes\\:\\ 0\\.017442432383994105\ \(0\)\
\-\ enhancement\\:\\ 0\\.017396117211061032\ \(0\)\
\-\ temporal\\:\\ 0\\.01732602976007158\ \(0\)\
\-\ necrosis\\:\\ 0\\.017078990954150403\ \(0\)\
\-\ spasticity\\:\\ 0\\.017053359195662435\ \(0\)\
\-\ bad\\:\\ 0\\.016755174295266528\ \(0\)\
\-\ suffers\\:\\ 0\\.016488438812588487\ \(0\)\
\-\ grade\\:\\ 0\\.016480186293422634\ \(0\)\
\-\ perilesional\\:\\ 0\\.01624714721814716\ \(0\)\
\-\ exaggerated\\:\\ 0\\.016026865251084804\ \(0\)\
\-\ aforementioned\\:\\ 0\\.015636610365446175\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.015508586253877799\ \(0\)\
\-\ clonus\\:\\ 0\\.015461944868010856\ \(0\)\
\-\ effect\\:\\ 0\\.015319282294021493\ \(0\)\
\-\ areas\\:\\ 0\\.014558719854410465\ \(0\)\
\-\ interestingly\\:\\ 0\\.014379808121613541\ \(0\)\
\-\ radiation\\:\\ 0\\.014198740504113096\ \(0\)\
\-\ june\\:\\ 0\\.014168715440755182\ \(0\)\
\-\ profile\\:\\ 0\\.014069422496063331\ \(0\)\
\-\ differential\\:\\ 0\\.013736505465078125\ \(0\)\
\-\ yrs\\:\\ 0\\.0137071418792515\ \(0\)\
\-\ list\\:\\ 0\\.013543753218143726\ \(0\)\
\-\ demyelinating\\:\\ 0\\.013390273162912246\ \(0\)\
\-\ clinical\\:\\ 0\\.013312961012992426\ \(0\)\
\-\ severe\\:\\ 0\\.013312961012992426\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.013176203826132339\ \(0\)\
\-\ confusion\\:\\ 0\\.012978832835069776\ \(0\)\
\-\ basis\\:\\ 0\\.012978832835069776\ \(0\)\
\-\ impairment\\:\\ 0\\.012916319891803014\ \(0\)\
\-\ gbm\\:\\ 0\\.01279574255258971\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.012680647934673871\ \(0\)\
\-\ effects\\:\\ 0\\.012625005132854186\ \(0\)\
\-\ screen\\:\\ 0\\.01257055904368719\ \(0\)\
\-\ multiforme\\:\\ 0\\.01257055904368719\ \(0\)\
\-\ his\\:\\ 0\\.012470324190617377\ \(0\)\
\-\ speech\\:\\ 0\\.01246505854647056\ \(0\)\
\-\ lymphoma\\:\\ 0\\.012365562705769549\ \(0\)\
\-\ \\,\\:\\ 0\\.012336154884332083\ \(0\)\
\-\ t2\\:\\ 0\\.012246019082280263\ \(0\)\
\-\ edema\\:\\ 0\\.0122375872882597\ \(0\)\
\-\ ill\\-defined\\:\\ 0\\.012219074373170187\ \(0\)\
\-\ encephalitis\\:\\ 0\\.012082195331979616\ \(0\)\
\-\ low\\:\\ 0\\.012031230647424809\ \(0\)\
\-\ compatible\\:\\ 0\\.011952338890492147\ \(0\)\
\-\ presented\\:\\ 0\\.011794215873531187\ \(0\)\
\-\ been\\:\\ 0\\.01177111336437464\ \(0\)\
\-\ lobe\\:\\ 0\\.011642153660372325\ \(0\)\
\-\ dizziness\\:\\ 0\\.011598511188276553\ \(0\)\
\-\ contains\\:\\ 0\\.011562084004853517\ \(0\)\
\-\ dysfunction\\:\\ 0\\.011526173536519451\ \(0\)\
\-\ we\\:\\ 0\\.011387418507418198\ \(0\)\
\-\ drug\\:\\ 0\\.011100510443349833\ \(0\)\
\-\ callosum\\:\\ 0\\.011100510443349833\ \(0\)\
\-\ hemisphere\\:\\ 0\\.011011671659017506\ \(0\)\
\-\ degeneration\\:\\ 0\\.010982738251869092\ \(0\)\
\-\ obvious\\:\\ 0\\.010925844945914516\ \(0\)\
\-\ characterized\\:\\ 0\\.01076245628480674\ \(0\)\
\-\ corpus\\:\\ 0\\.010659109463236472\ \(0\)\
\-\ undergoing\\:\\ 0\\.010608976229575257\ \(0\)\
\-\ almost\\:\\ 0\\.010464271384410832\ \(0\)\
\-\ hypointense\\:\\ 0\\.010261631618148715\ \(0\)\
\-\ reflexes\\:\\ 0\\.01024008556835654\ \(0\)\
\-\ tendon\\:\\ 0\\.010094189080162524\ \(0\)\
\-\ main\\:\\ 0\\.010074016498772204\ \(0\)\
\-\ ring\\:\\ 0\\.010054003386095968\ \(0\)\
\-\ so\\:\\ 0\\.0098437081995172\ \(0\)\
\-\ visual\\:\\ 0\\.009807281016094162\ \(0\)\
\-\ glioma\\:\\ 0\\.009753604541029344\ \(0\)\
\-\ reveal\\:\\ 0\\.009632615518658842\ \(0\)\
\-\ difficulty\\:\\ 0\\.009632615518658842\ \(0\)\
\-\ in\\:\\ 0\\.009601455876613403\ \(0\)\
\-\ demonstrates\\:\\ 0\\.009451246590649044\ \(0\)\
\-\ extends\\:\\ 0\\.009376026925594824\ \(0\)\
\-\ have\\:\\ 0\\.0093693067258992\ \(0\)\
\-\ neurological\\:\\ 0\\.009360821801391755\ \(0\)\
\-\ affected\\:\\ 0\\.009360821801391755\ \(0\)\
\-\ \\(\\:\\ 0\\.009143819319542537\ \(0\)\
\-\ features\\:\\ 0\\.009129195623101462\ \(0\)\
\-\ increase\\:\\ 0\\.009074455207878257\ \(0\)\
\-\ condition\\:\\ 0\\.009047522554194571\ \(0\)\
\-\ motor\\:\\ 0\\.009034162915964587\ \(0\)\
\-\ \\)\\:\\ 0\\.009032122684978544\ \(0\)\
\-\ hyperintense\\:\\ 0\\.008981418392159924\ \(0\)\
\-\ infarction\\:\\ 0\\.008841793531210354\ \(0\)\
\-\ deep\\:\\ 0\\.008756790251378445\ \(0\)\
\-\ enlargement\\:\\ 0\\.008583717484772393\ \(0\)\
\-\ currently\\:\\ 0\\.008572589354460905\ \(0\)\
\-\ diagnostic\\:\\ 0\\.008572589354460905\ \(0\)\
\-\ progressive\\:\\ 0\\.008550478772261526\ \(0\)\
\-\ matter\\:\\ 0\\.00851767081114126\ \(0\)\
\-\ reveals\\:\\ 0\\.008463918355177274\ \(0\)\
\-\ the\\:\\ 0\\.008399956538954478\ \(0\)\
\-\ note\\:\\ 0\\.008349532981017191\ \(0\)\
\-\ pattern\\:\\ 0\\.00826947427612982\ \(0\)\
\-\ http\\:\\ 0\\.008191869868304495\ \(0\)\
\-\ course\\:\\ 0\\.008163370742925674\ \(0\)\
\-\ has\\:\\ 0\\.00812506314174318\ \(0\)\
\-\ a\\:\\ 0\\.00803240104949066\ \(0\)\
\-\ presence\\:\\ 0\\.007852621818878807\ \(0\)\
\-\ malignant\\:\\ 0\\.007819419433871648\ \(0\)\
\-\ did\\:\\ 0\\.007811186432893478\ \(0\)\
\-\ later\\:\\ 0\\.007811186432893478\ \(0\)\
\-\ biopsy\\:\\ 0\\.007675172763637369\ \(0\)\
\-\ signs\\:\\ 0\\.0076136099594583655\ \(0\)\
\-\ cerebral\\:\\ 0\\.007494801270288787\ \(0\)\
\-\ underwent\\:\\ 0\\.007423281102476505\ \(0\)\
\-\ now\\:\\ 0\\.007395229341016829\ \(0\)\
\-\ three\\:\\ 0\\.0072927195654352165\ \(0\)\
\-\ first\\:\\ 0\\.0072594517336350695\ \(0\)\
\-\ size\\:\\ 0\\.007252850307288029\ \(0\)\
\-\ by\\:\\ 0\\.0072044096366829105\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.0072006495801924955\ \(0\)\
\-\ white\\:\\ 0\\.007174947373954475\ \(0\)\
\-\ showed\\:\\ 0\\.007093172830186574\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.007038068332763904\ \(0\)\
\-\ medial\\:\\ 0\\.006919745604025448\ \(0\)\
\-\ t1\\:\\ 0\\.006856950724618339\ \(0\)\
\-\ onset\\:\\ 0\\.006828914496013038\ \(0\)\
\-\ post\\:\\ 0\\.00681224059005644\ \(0\)\
\-\ examination\\:\\ 0\\.006725121608796368\ \(0\)\
\-\ some\\:\\ 0\\.0065694386173842005\ \(0\)\
\-\ as\\:\\ 0\\.006544696232375331\ \(0\)\
\-\ negative\\:\\ 0\\.006461063699683226\ \(0\)\
\-\ from\\:\\ 0\\.006412332724831455\ \(0\)\
\-\ primary\\:\\ 0\\.00640856775416632\ \(0\)\
\-\ years\\:\\ 0\\.006352514270932867\ \(0\)\
\-\ changes\\:\\ 0\\.006200121458822938\ \(0\)\
\-\ through\\:\\ 0\\.006144194983343972\ \(0\)\
\-\ all\\:\\ 0\\.00611879364412985\ \(0\)\
\-\ secondary\\:\\ 0\\.006048177130402044\ \(0\)\
\-\ performed\\:\\ 0\\.006031843876524858\ \(0\)\
\-\ mass\\:\\ 0\\.006017524085810453\ \(0\)\
\-\ an\\:\\ 0\\.005983113236884708\ \(0\)\
\-\ shows\\:\\ 0\\.005947781518300959\ \(0\)\
\-\ high\\:\\ 0\\.005920369774878014\ \(0\)\
\-\ are\\:\\ 0\\.005898095557111908\ \(0\)\
\-\ due\\:\\ 0\\.005772853551779341\ \(0\)\
\-\ evidence\\:\\ 0\\.005672006540169311\ \(0\)\
\-\ of\\:\\ 0\\.005603980291548811\ \(0\)\
\-\ anterior\\:\\ 0\\.005571627401930981\ \(0\)\
\-\ and\\:\\ 0\\.005468628022244611\ \(0\)\
\-\ acute\\:\\ 0\\.005341466655965811\ \(0\)\
\-\ man\\:\\ 0\\.005116283147063289\ \(0\)\
\-\ associated\\:\\ 0\\.005104968511158739\ \(0\)\
\-\ 3\\:\\ 0\\.005065760827105164\ \(0\)\
\-\ tumor\\:\\ 0\\.00504362608002737\ \(0\)\
\-\ was\\:\\ 0\\.005003936821335123\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0049676438753934685\ \(0\)\
\-\ well\\:\\ 0\\.004893875830300382\ \(0\)\
\-\ contrast\\:\\ 0\\.004842470093184571\ \(0\)\
\-\ left\\:\\ 0\\.0048410393380907074\ \(0\)\
\-\ treatment\\:\\ 0\\.004378777112913638\ \(0\)\
\-\ no\\:\\ 0\\.004356679244069884\ \(0\)\
\-\ patient\\:\\ 0\\.004337174333753863\ \(0\)\
\-\ is\\:\\ 0\\.004270562873808043\ \(0\)\
\-\ also\\:\\ 0\\.0042648597308105095\ \(0\)\
\-\ images\\:\\ 0\\.004150035169492036\ \(0\)\
\-\ which\\:\\ 0\\.004038340727196326\ \(0\)\
\-\ that\\:\\ 0\\.0037366600723008187\ \(0\)\
\-\ for\\:\\ 0\\.0036916868285707095\ \(0\)\
\-\ on\\:\\ 0\\.003665270948685712\ \(0\)\
\-\ disease\\:\\ 0\\.003536044408141023\ \(0\)\
\-\ to\\:\\ 0\\.003243555253997364\ \(0\)\
\-\ there\\:\\ 0\\.0032195330543417435\ \(0\)\
\-\ \\:\\:\\ 0\\.002861455230356114\ \(0\)\
\-\ or\\:\\ 0\\.002535500630287867\ \(0\)\
\-\ right\\:\\ 0\\.0022826119217985233\ \(0\)\
\-\ \\.\\:\\ 0\\.00188731710897284\ \(0\)\
\-\ with\\:\\ 0\\.0008886393120751118\ \(0\)\
